Drugs / recwt1-A10+AS01B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01819558 | Mar 2013 → Mar 2015 | acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome | Institut Paoli-Calmettes | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recwt1-A10+AS01B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01819558 ↗ |
| Modality | Protein / enzyme biologic | “6 administration every 2 weeks of intra-muscular 200 micrograms of protein recwt1-A10+AS01B at week 1, 3, 5, 7, 9 and 11.” NCT01819558 ↗ |
| Route | Intramuscular | “intra-muscular 200 micrograms of protein recwt1-A10+AS01B” NCT01819558 ↗ |